Navigation Links
Exelixis Announces June 5 Webcast of Conference Call Regarding Its $150 Million Funding Commitment from Deerfield Management
Date:6/5/2008

SOUTH SAN FRANCISCO, Calif., June 5 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) announced earlier today that it has received a $150.0 million funding commitment from Deerfield Management. The arrangement will be discussed by Exelixis management in a live conference call at 5:00 a.m. PT/8:00 a.m. ET today, Thursday, June 5. To listen to a webcast of the discussion, visit the Event Calendar page under Investors at http://www.exelixis.com.

A replay of the conference call will be available until 7:00 a.m. PT/10:00 a.m. ET on July 5, 2008. Access numbers for the replay are: 1-888-286-8010 (domestic) and 1-617-801-6888 (international), and the passcode is 33494166.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's website at http://www.exelixis.com.


'/>"/>
SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Exelixis Announces June 10 Webcast of Presentation at the Goldman Sachs 29th Annual Global Healthcare Conference
2. REMINDER: Exelixis Will Webcast Its June 2 Investor and Analyst Briefing at ASCO
3. Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing
4. Exelixis Announces May 13 Webcast of Presentation at the Bank of America Health Care Conference
5. Exelixis Announces May 6 Webcast of Its First Quarter 2008 Financial Results and Business Update Conference Call
6. Exelixis Announces April 30 Webcast of Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
7. Seven Abstracts Featuring Exelixis Compounds Accepted for Presentation at 2008 ASCO Annual Meeting
8. Option to Develop Exelixis Compound Exercised By Genentech
9. Exelixis Announces March 17 Webcast of Presentation at the Cowen and Company Annual Health Care Conference
10. Exelixis Announces March 4 Webcast of Presentation at the Susquehanna SIGnificant Options in Healthcare Conference
11. Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Boston, MA (PRWEB) January 14, 2014 ... today announces Michelle Detwiler as the new Director of ... current and potential clients as well as iLab sub-teams ... main goal will be to ensure that iLab provides ... offering the most advanced, user-friendly, and high-impact solution in ...
(Date:1/14/2014)... WESTBOROUGH, Mass. , Jan. 14, 2014 ... biotechnology company focused on discovering, developing and ... needs using RNA-targeted technologies, today announced that ... the United States Patent and Trademark Office ... for the treatment of fibrosis. The patent ...
(Date:1/14/2014)... , Jan. 14, 2014   Kinaxis ®, ... management ( SCM ) and sales and operations planning ... gold sponsor of the Biomanufacturing Summit , which ... January 30 – 31, 2014.  At the conference, join ... Chain at Amgen, as she presents ,Supply Chain: Improving ...
(Date:1/14/2014)... Kerr Corporation, a leading manufacturer of innovative dental products, ... dual arch impressions on its dental blog. , ... entry serves up a list of tips to help dentists ... Dr. David Little as he crafts a porcelain crown using ... as the dual arch dental impression material . ...
Breaking Biology Technology:iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... Pressure BioSciences, Inc. (Nasdaq: PBIO ) ... announced that they have entered into a strategic marketing, ... the Agreement, the companies will: (1) share market data, ... certain products at industry trade shows beginning in 2009; ...
... http://www.wellcentive.com ),today announced the launch of two new ... securely and cost-effectively share patient,data within a community ... such as physicians, to easily access patient data ... Connect is a health care technology platform,which receives ...
... NEW YORK, Dec. 11 Delcath Systems, Inc. (Nasdaq: ... its proprietary Percutaneous Hepatic Perfusion ("PHP") System for the treatment ... fifty percent (46 of 92) of patients have been enrolled ... ocular melanoma to the liver. The eleven participating cancer ...
Cached Biology Technology:Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement 2Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement 3Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement 4Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement 5WellCentive Launches New Health Information Exchange Platforms 2WellCentive Launches New Health Information Exchange Platforms 3Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point 2Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point 3
(Date:4/16/2014)... to blame for significant baseline levels of arsenic in ... in the Journal of Environmental Quality . , ... of Ohio showed that every single sample had concentrations ... the U.S. Environmental Protection Agency. The findings should not ... regulatory levels typically are set far below those thought ...
(Date:4/15/2014)... and energy for nearly all life on Earth, yet ... example, little is known about how it is regulated ... we do not know the full list of the ... any organism. , , A type of single-cell green ... subject for photosynthesis research. Despite its importance in the ...
(Date:4/15/2014)... Worcester, Mass. Diana Lados, associate professor ... (WPI) and founding director of the university,s ... two major career achievement awards from leading ... in Detroit, SAE International, a global association ... technical experts in the automotive, aerospace, and ...
Breaking Biology News(10 mins):Significant baseline levels of arsenic found in Ohio soils are due to natural processes 2Significant baseline levels of arsenic found in Ohio soils are due to natural processes 3Significant baseline levels of arsenic found in Ohio soils are due to natural processes 4WPI's Diana Lados honored by SAE International and Minerals, Metals, and Materials Society 2WPI's Diana Lados honored by SAE International and Minerals, Metals, and Materials Society 3WPI's Diana Lados honored by SAE International and Minerals, Metals, and Materials Society 4WPI's Diana Lados honored by SAE International and Minerals, Metals, and Materials Society 5
... Jerusalem, November 21, 2010 Research work carried out ... warning in the growing field of the development of ... patients through replacement of diseased or damaged tissues by ... a possible danger of cancerous tissue development in the ...
... Consortium (IVCC) has received $50 million from the Bill ... develop new insecticides for the improved control of mosquitoes ... neglected tropical diseases. IVCC was established ... over five years from the foundation. Since then, ...
... prompts normal cells to transform themselves into cancerous cells? Researchers ... Antonio, have identified factors in the very first step of ... tube. The latter accomplishment was reported Sunday [Nov. 21] in ... The DNA molecule the elegant, twin-stranded necklace of ...
Cached Biology News:Hebrew University research carries cautionary warning for future stem cell applications 2Hebrew University research carries cautionary warning for future stem cell applications 3
COMING SOON: Anti-Mouse C5/C5b, Clone BB5.1. Monoclonal Antibody...
... Goat anti-Human Alpha 1 Acid ... azide Goats were immunized ... glycoprotein in Freund's adjuvant. ... absorbed to ensure specificity. ...
Anti-Mouse Valpha 2 TCR, Purified (Clone B20.1) (rat IgG2a)...
Request Info...
Biology Products: